Send to

Choose Destination
See comment in PubMed Commons below
Am J Manag Care. 2006 Dec;12(17 Suppl):S473-83.

Decreasing risk: impact of HPV vaccination on outcomes.

Author information

Cisco Systems, 170 Tasman Dr, Bldg 5-3, San Jose, CA 95134, USA.


Cervical cancer, caused by oncogenic types of human papillomavirus (HPV), remains a major health problem worldwide. The recent introduction of a quadrivalent vaccine (Gardasil), which targets HPV strains responsible for approximately 70% of cervical cancer cases and 90% of genital warts, has ushered in new hope of substantially reducing global prevalence of HPV disease. A further bivalent HPV vaccine (Cervarix) is in the offing. However, many issues still need to be addressed, including actual vaccine efficacy in preventing cervical cancer, public acceptance, use of the vaccine in men, vaccine access, costs, and impact of the vaccine on cervical cancer screening programs. This review analyzes some of these issues, and emphasizes the need for a coordinated effort of patients, parents, health professionals, hospitals, and policymakers to ensure successful implementation of vaccination programs in the United States.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Managed Care & Healthcare Communications, LLC
    Loading ...
    Support Center